Can-Fite BioPharma (TASE:CANF) - Hisse Senedi Fiyatı, Haberler ve Analizler

CANF Stoklara Genel Bakış

Klinik aşamada bir biyofarmasötik şirketi olan Can-Fite BioPharma Ltd. İsrail'de kanser, karaciğer iltihabı hastalıkları ve erektil disfonksiyon tedavisi için oral yoldan biyolojik olarak kullanılabilir küçük moleküllü terapötik ürünler geliştirmektedir. Daha fazla detay

CANF temel anali̇z
Kar Tanesi Skoru
Değerleme	2/6
Gelecekteki Büyüme	2/6
Geçmiş Performans	0/6
Finansal Sağlık	5/6
Temettüler	0/6

Ödüller

Adil değer tahminimizden 99.8% daha düşük bir oranda işlem görüyor

Gelirin yılda 67.16% oranında artması öngörülüyor

Kazançlar son 5 yılda yılda 7.8% oranında arttı

Risk Analizi

Son 3 ayda hisse senedi fiyatı oldukça dalgalıydı

Hissedarlar geçen yıl önemli ölçüde sulandırıldı

Geliri 1 milyon ABD dolarından az ( $667K )

Anlamlı bir piyasa değeri yok ( ₪53M )

+ 1 daha fazla risk

Can-Fite BioPharma Ltd. Rakipler

Evogene

TASE:EVGN

₪31.7m

Kamada

TASE:KMDA

₪1.2b

BioLineRx

TASE:BLRX

₪90.0m

Univo Pharmaceuticals

TASE:UNVO

₪2.8m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Can-Fite BioPharma
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	₪0.026
52 Haftanın En Yüksek Seviyesi	₪0.056
52 Haftanın En Düşük Seviyesi	₪0.025
Beta	0.57
11 Aylık Değişim	-25.71%
3 Aylık Değişim	-13.33%
1 Yıllık Değişim	-3.70%
33 Yıllık Değişim	-80.45%
5 Yıllık Değişim	-93.26%
Halka arzdan bu yana değişim	-99.92%

Son Haberler & Güncellemeler

Recent updates

It's Unlikely That Can-Fite BioPharma Ltd.'s (TLV:CANF) CEO Will See A Huge Pay Rise This Year

Jun 19

Hissedar Getirileri

	CANF	IL Biotechs	IL Pazar
7D	0%	-4.2%	1.0%
1Y	-3.7%	-10.1%	23.7%

Getiri vs. Endüstri: CANF geçen yıl % -10.1 oranında getiri sağlayan IL Biotechs sektörünü aştı.

Getiri vs Piyasa: CANF geçen yıl % 23.7 oranında getiri sağlayan IL Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is CANF's price volatile compared to industry and market?
CANF volatility
CANF Average Weekly Movement	7.8%
Biotechs Industry Average Movement	4.9%
Market Average Movement	4.0%
10% most volatile stocks in IL Market	7.3%
10% least volatile stocks in IL Market	2.9%

İstikrarlı Hisse Senedi Fiyatı: CANF hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: CANF 'nin haftalık oynaklığı ( 8% ) geçen yıl boyunca sabit kaldı, ancak hala IL hisselerinin %75'inden yüksek.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
1994	8	Motti Farbstein	www.canfite.com

Klinik aşamada bir biyofarmasötik şirketi olan Can-Fite BioPharma Ltd. İsrail'de kanser, karaciğer iltihabı hastalıkları ve erektil disfonksiyon tedavisi için ağızdan alınabilen küçük moleküllü terapötik ürünler geliştirmektedir. Şirketin öncü ilaç adayı Piclidenoson, sedef hastalığının tedavisi için Faz III klinik çalışmasını tamamlamıştır.

Can-Fite BioPharma Ltd. Temel Bilgiler Özeti

Can-Fite BioPharma'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
CANF temel i̇stati̇sti̇kler
Piyasa değeri	₪53.15m
Kazançlar(TTM)	-₪27.10m
Gelir(TTM)	₪2.45m

21.7x

P/S Oranı

-2.0x

F/K Oranı

CANF aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
CANF gelir tablosu (TTM)
Gelir	US$667.00k
Gelir Maliyeti	US$0
Brüt Kâr	US$667.00k
Diğer Giderler	US$8.04m
Kazançlar	-US$7.37m

Son Raporlanan Kazançlar

Jun 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-0.0036
Brüt Marj	100.00%
Net Kâr Marjı	-1,105.10%
Borç/Özkaynak Oranı	0%

CANF uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

CANF Stoklara Genel Bakış

Ödüller

Risk Analizi

Can-Fite BioPharma Ltd. Rakipler

TASE:EVGN

₪31.7m

TASE:KMDA

₪1.2b

TASE:BLRX

₪90.0m

TASE:UNVO

₪2.8m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Can-Fite BioPharma Ltd. Achieves Milestone with First Patient Dosing in Pancreatic Cancer Phase IIa Clinical Trial

Can-Fite BioPharma Ltd.'s Partner Vetbiolix Reports Positive Results in Dog Osteoarthritis Study with Piclidenoson

Can-Fite BioPharma Ltd. Receives Approval from Israeli Ministry of Health to Conduct Phase IIa Clinical Trial with Orally-Administered Namodenoson in Treatment of Pancreatic Carcinoma

New major risk - Shareholder dilution

Insufficient new directors

First half 2024 earnings released: US$0.002 loss per share (vs US$0.004 loss in 1H 2023)

Recent updates

Can-Fite BioPharma Ltd. Achieves Milestone with First Patient Dosing in Pancreatic Cancer Phase IIa Clinical Trial

Can-Fite BioPharma Ltd.'s Partner Vetbiolix Reports Positive Results in Dog Osteoarthritis Study with Piclidenoson

Can-Fite BioPharma Ltd. Receives Approval from Israeli Ministry of Health to Conduct Phase IIa Clinical Trial with Orally-Administered Namodenoson in Treatment of Pancreatic Carcinoma

New major risk - Shareholder dilution

Insufficient new directors

First half 2024 earnings released: US$0.002 loss per share (vs US$0.004 loss in 1H 2023)

Can-Fite BioPharma Ltd. Announces Improvement in Patient with Decompensated Liver Cirrhosis Upon Treatment with Namodenoson

Can-Fite BioPharma Ltd. Announces Positive Results from Osteoarthritis Clinical Study in Dogs Reported by Vetbiolix

Can-Fite Announces Breakthrough Findings Demonstrate Namodenoson Anti-Cancer and Protective Effect Mechanism in the Liver

It's Unlikely That Can-Fite BioPharma Ltd.'s (TLV:CANF) CEO Will See A Huge Pay Rise This Year

Can-Fite Biopharma Ltd. Receives IRB Approval for the Treatment of Pancreatic Cancer with Namodenoson in a Phase IIa Study

Can-Fite Biopharma Ltd. Updates on Its Advanced Liver Cancer Pivotal Phase 3 Study

Can-Fite BioPharma Ltd., Annual General Meeting, Jun 26, 2024

New minor risk - Share price stability

Can-Fite BioPharma Ltd. Announces FDA Grants IND Clearance for Namodenoson to Treat MASH Patients in a Phase IIb Study

Can-Fite BioPharma Ltd. Receives Notice of Allowance from the European Patent Office for the Treatment of Erectile Dysfunction with CF602

No longer forecast to breakeven

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

Can-Fite BioPharma Ltd. Reports New Data on Namodenoson’s Anti-Obesity Mechanism of Action

Can-Fite BioPharma Ltd. Receives Positive Response from U.S. Food and Drug Administration on Pediatric Study Plan for Treatment of Children Suffering from Psoriasis with Piclidenoson

Can-Fite BioPharma Ltd. Completes the Design of a Phase IIa Study Protocol for the Treatment of Pancreatic Cancer Patients

Third quarter 2023 earnings released: US$0.001 loss per share (vs US$0.003 loss in 3Q 2022)

Can-Fite Biopharma Ltd. Announces Complete Response and 6.9 Years Overall Survival in A Patient with Advanced Liver Cancer Treated with Namodenoson

Can-Fite Biopharma Ltd. Provides Business Update

Can-Fite Biopharma Ltd. Announces Namodenoson Inhibits Pancreatic Carcinoma Published in Leading Scientific Journal

New minor risk - Share price stability

New major risk - Market cap size

New major risk - Financial data availability

First half 2023 earnings released: US$0.004 loss per share (vs US$0.006 loss in 1H 2022)

Can-Fite Enters Rare Genetic Disease Field Based on Impactful Findings of A Fondazione Telethon and Naples University Researcher Showing Piclidenoson Is Efficacious in Treating Lowe Syndrome

Can-Fite Biopharma Ltd. Submits Pediatric Plan to U.S. Food and Drug Administration to Allow Registration of Piclidenoson for the Treatment of Adolescents with Psoriasis

New major risk - Revenue and earnings growth

No longer forecast to breakeven

Can-Fite Biopharma Ltd. Receives U.S. FDA's Go Ahead for Piclidenoson Psoriasis Registration Plan

Can-Fite BioPharma Ltd., Annual General Meeting, Jul 31, 2023

Can-Fite BioPharma Ltd. to Submit IND for the Treatment of Pancreatic Cancer Patients with Namodenoson

First quarter 2023 earnings released: US$0.002 loss per share (vs US$0.003 loss in 1Q 2022)

Can-Fite BioPharma Ltd. to Initiate Exploratory Phase 2 Trial with Namodenoson in Pancreatic Cancer Patients

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

No longer forecast to breakeven

No longer forecast to breakeven

Can-Fite Biopharma Ltd. Announces Namodenoson Is Approved for Compassionate Use in the Treatment of Liver Cancer in Israel and Romania

Third quarter 2022 earnings released: US$0.003 loss per share (vs US$0.006 loss in 3Q 2021)

Can-Fite BioPharma Ltd. Announces Namodenoson Significantly Inhibits Pancreatic Cancer in Preclinical Studies

Can-Fite BioPharma Ltd. Submits Market Registration Plan to European Medicines Agency for Piclidenoson in the Treatment of Psoriasis; U.S. Food and Drug Administration Submission to Follow

Can-Fite Biopharma Ltd Provides Update on Its Clinical Program for Namodenoson in the Treatment of Hepatocellular Carcinoma

Third quarter 2022 earnings released: US$0.003 loss per share (vs US$0.006 loss in 3Q 2021)

Insufficient new directors

Can-Fite BioPharma Ltd.: New Phase III Psoriasis Data Showing Superior Safety & Improved Efficacy Presented by KOL Dr. Papp at the 31st European Academy of Dermatology

Second quarter 2022 earnings released: US$0.003 loss per share (vs US$0.006 loss in 2Q 2021)

Forecast to breakeven in 2023

Can-Fite BioPharma Ltd’s Drug Namodenoson Approves for Compassionate Use Treatment of Advanced Liver Cancer Patients in Romania

Can-Fite BioPharma Ltd. Reports Progress in the Development of Piclidenoson for Osteoarthritis in Pets Through Its Partner Vetbiolix

Can-Fite BioPharma Ltd., Annual General Meeting, Aug 29, 2022

Can-Fite BioPharma Ltd. to Submit FDA & EMA Registration Plans for Piclidenoson in the Oral Treatment of Moderate to Severe Psoriasis

Can-Fite BioPharma Ltd. Announces Positive Top-Line Results from Piclidenoson Phase III COMFORT Study in Moderate to Severe Psoriasis

Is Can-Fite BioPharma (TLV:CANF) In A Good Position To Invest In Growth?

First quarter 2022 earnings released: US$0.003 loss per share (vs US$0.004 loss in 1Q 2021)

Can-Fite BioPharma Ltd. Receives Key NASH Patent in Israel